Indivior (INDV) Expected to Announce Quarterly Earnings on Thursday

Indivior (NASDAQ:INDV) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Indivior to post earnings of $0.65 per share and revenue of $305.62 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Indivior Stock Performance

NASDAQ:INDV opened at $34.36 on Thursday. Indivior has a one year low of $7.62 and a one year high of $38.00. The business’s 50-day simple moving average is $34.84 and its 200 day simple moving average is $29.48. The stock has a market cap of $4.30 billion, a price-to-earnings ratio of 37.35 and a beta of 0.80.

Insider Transactions at Indivior

In other Indivior news, Director Mark Stejbach bought 775 shares of Indivior stock in a transaction dated Monday, January 5th. The stock was bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. The trade was a 4.82% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara Ryan acquired 775 shares of Indivior stock in a transaction on Monday, January 5th. The shares were bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 4,871 shares of company stock valued at $172,385.

Institutional Trading of Indivior

Several large investors have recently bought and sold shares of the business. Quarry LP acquired a new position in Indivior in the 3rd quarter worth about $26,000. Raymond James Financial Inc. acquired a new stake in Indivior during the 2nd quarter worth about $26,000. Aquatic Capital Management LLC bought a new stake in Indivior in the third quarter worth approximately $104,000. Landscape Capital Management L.L.C. acquired a new position in shares of Indivior during the 4th quarter valued at $205,000. Finally, Virtus Advisers LLC acquired a new stake in shares of Indivior in the 4th quarter valued at about $215,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $41.00 target price (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Northland Securities set a $50.00 price target on Indivior in a report on Tuesday, January 20th. HC Wainwright lifted their price objective on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research report on Wednesday, January 28th. Finally, Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Indivior currently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.